Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Aromasin-Related Bone Loss Affected by Vitamin D Levels

September 1, 2006
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

The bone loss associated with adjuvant exemestane (Aromasin) therapy for breast cancer tends to be greater in women who have suboptimal levels of vitamin D

ATLANTA — The bone loss associated with adjuvant exemestane (Aromasin) therapy for breast cancer tends to be greater in women who have suboptimal levels of vitamin D, Per E. Lønning, MD, PhD, reported at the 42nd Annual Meeting of the American Society of Clinical Oncology (abstract 554).

A randomized trial among women treated for early breast cancer or ductal carcinoma in situ found that, compared with placebo, exemestane at a dose of 25 mg daily was associated with a significant increase in the annual rate of loss of bone mineral density (BMD) in the femoral neck (2.7% vs 1.5%) and a nonsignificant increase in the lumbar spine (2.2% vs 1.8%) after 2 years of treatment (J Clin Oncol 23:5126-5137, 2005).

"The surprise was that in both arms, the annual bone loss was somewhat higher than what was expected in general from the literature," said Dr. Lønning, of Haukeland University Hospital, Bergen, Norway. "That led us into this subinvestigation, to explore the reasons for this increased bone loss in the whole population of patients, whether they received placebo or exemestane."

The researchers analyzed data on a variety of biomarkers (25-hydroxyvitamin D, calcium, estrogen, and parathyroid hormone) that had been collected at baseline and after 6, 12, 18, and 24 months of treatment.

In all, 147 patients participated in the trial. At baseline assessment, 128 of these patients (88%) had a suboptimal concentration of vitamin D, defined as a level of less than 30 ng/mL.

In the study population overall, body mass index at baseline was significantly correlated with BMD of the femoral neck, Dr. Lønning said. In contrast, vitamin D level at baseline was not, although he noted that analyses were limited by the small number of patients studied and the fact that many other factors likely influenced BMD.

At the femoral neck, the mean change in BMD at 2 years among patients with suboptimal vitamin D status at baseline tended to be greater with exemestane therapy than with placebo (-4.70% vs -3.02%), Dr. Lønning said, but there was little difference by treatment arm among patients with optimal vitamin D status (-3.67% vs -3.29%).

At the lumbar spine, the mean change in BMD also tended to be greater with exemestane (-3.42% vs -2.47%), but the difference was more marked among patients with optimal vitamin D status (-4.31% vs -0.61%).

Impact on Compact Bone

The contrasting findings in the femoral neck and hip could be due to chance, Dr. Lønning said, but he noted that vitamin D status has more impact on compact bone than trabecular bone status. "So it may well be that there is a physiological explanation, and this could be an indication that the interaction of low vitamin D status and low estrogen levels could be detrimental," he said.

The fact that most study patients had suboptimal vitamin D levels was a concern, he said, and possible explanatory factors might include ethnicity and geographic location.

"There have been suggestions in the literature that low vitamin D status could be a risk factor for breast cancer," he said. "So it may be—and this has not been properly examined—that breast cancer patients on average have a poorer vitamin D status than the normal population in general."

Vitamin D Supplementation

Vitamin D supplementation may be important for maintaining bone health in postmenopausal women with breast cancer who receive adjuvant therapy with aromatase inhibitors, Dr. Lønning commented. "This study highlights that there is a need to look into these issues of breast cancer treatment, bone health, and vitamin D status," he said.

Articles in this issue

Exjade Gains Approval in EU
Study Questions the Need for Maintenance Therapy in Metastatic Colorectal Cancer
President's Cancer Panel Assesses Progress in Two Areas
Proposed Medicare OPPS Rule Draws Fire for Its 'Inadequate Reimbursement'
Cognitive Rx Reduces Depression in Breast Ca Pts
Nurses Develop Evidence-Based Guidelines for Mucositis
Anastrozole Therapy for Breast Cancer Affects Bone Health
Is Demand for Trial Subjects Outpacing Supply?
Postchemo Disappearance of Liver Mets Doesn't Mean Cure
Aromasin-Related Bone Loss Affected by Vitamin D Levels
Melanoma Mets Regress After Gene Therapy
Phase I/II Trial of AGS-003
Short Course of Preoperative Radiotherapy Improves Outcomes in Patients With Resectable Rectal Cancer
President Bush Names Niederhuber NCI Director
Lack of EGFR Expression in Colon Ca Can Be Misleading
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Advertisement

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer

Russ Conroy
September 25th 2025
Article

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

ONCOLOGY Staff
September 23rd 2025
Article

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 9th 2025
Article

THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.


Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Trastuzumab Pamirtecan Improves PFS in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
September 7th 2025
Article

Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Related Content
Advertisement

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer

Russ Conroy
September 25th 2025
Article

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

ONCOLOGY Staff
September 23rd 2025
Article

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 9th 2025
Article

THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.


Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Trastuzumab Pamirtecan Improves PFS in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
September 7th 2025
Article

Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.